IDX184: Phase IIa started

Idenix began a double-blind, placebo-controlled, dose-escalation Phase IIa trial to evaluate 50-200 mg daily of oral IDX184 plus peglyated interferon and ribavirin in 80 treatment-naïve patients with ...